arrow_back Back Filing freshness 10-Q Q1 FY2026 SEC EDGAR

BioXcel Therapeutics, Inc.

BTAI
$0.92 ▲ +0.09 (+10.84%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
38 Visible periods
26 Metrics
Peer-ranked Benchmarks
Price Chart
80
Health
Excellent
Bullish
auto_awesome

Analytical Summary

BioXcel Therapeutics, Inc. shows strong fundamentals with top-quartile Return on Common Equity (%) and Debt to Equity. The company's metrics support a bullish outlook for growth-oriented investors.

Market Cap $21.7M
Dividend Yield
Revenue Growth 22.6%
Op. Margin
ROIC 153.7%
FCF / Share $-0.50
Trailing P/E
Price / Book
FCF Yield
Debt / Equity -0.95
info Valuation on last close. End-of-day price, Aug 7, 2026.

38-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$206.00K
↑ +22.6%
Net Income Profit after all expenses
$-12.69M
↓ -75.0%
FCF / Share Free cash flow per share
$-0.50
↑ +79.9%
Long-Term Debt Long-term obligations
$100.29M
↓ -8.5%
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Return on Common Equity (%)Return on Common Equity (%) is in the top quartile
warning

Bearish Risks

  • No bearish risks detected.

Health Breakdown

Returns
98
Financial Health
70
Cash Quality
56

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 10 years · 38 quarters